all cryptocurrency companies Block

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Deutsche Bank: There is little hope that the British economy will rebound at the end of the year. Sanjay Raja, an economist at Deutsche Bank, wrote in a research report that the British economy will face more twists and turns in the future. Data released on Friday showed that Britain's GDP contracted again in October from the previous month, which surprised the market. Raja said that business surveys predict that economic activity will further weaken in the last few months of this year. In his research report, he reminded investors that the uncertainty in taxation and expenditure, coupled with the reduction in retail and service consumption caused by bad weather, added more resistance to Britain's fragile economic recovery.Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.

The public security organs that cracked down on the rectification of the "money-changing party" found that the funds involved were more than 80 billion yuan. It was learned from the press conference of the Ministry of Public Security that in May this year, the Ministry of Public Security deployed a special work to crack down on the rectification of the "money-changing party" and derivative crimes. Since the special action, it has been found that the funds involved have flowed more than 80 billion yuan. (Xinhua News Agency)Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)It is reported that Canada is considering imposing export taxes on commodities such as uranium and oil to counter Trump's tariff threat. Canada is studying the imposition of export taxes on major commodities exported to the United States, including uranium, oil and potash, in the case that Trump fulfills the comprehensive tariff threat. Officials familiar with the internal discussions of Canadian Prime Minister Trudeau's government said that the export tax would be Canada's last resort. According to people familiar with the matter, retaliatory tariffs on goods made in the United States and export controls on some Canadian products are more likely to come first. However, these officials said that if Trump decides to launch a full-scale trade war, the commodity export tax is a practical option, which will push up the costs of American consumers, farmers and enterprises. They said that the Trudeau government may also propose to expand its export control power in the latest report on the country's financial and economic situation scheduled to be released on Monday. It is reported that Canada is currently the largest external oil supplier in the United States. Some refineries rely on cheaper Canadian heavy crude oil, and there are few other options. The impact of rising costs is particularly severe in the Midwest of the United States, where nearly half of the crude oil used by fuel producers to produce gasoline and diesel comes from Canada.